HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin-Seok Ahn, Bohuslav Melichar, Shin-Cheh Chen, Sung-Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, Georg Kunz, Silvia Falcon, Shou-Tung Chen, Aulde Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot European Journal of Cancer Volume 62, Pages (July 2016) DOI: /j.ejca Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
Fig. 1 European Journal of Cancer , 62-75DOI: ( /j.ejca ) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
Fig. 2 European Journal of Cancer , 62-75DOI: ( /j.ejca ) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
Fig. 3 European Journal of Cancer , 62-75DOI: ( /j.ejca ) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
Fig. 4 European Journal of Cancer , 62-75DOI: ( /j.ejca ) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
Fig. 5 European Journal of Cancer , 62-75DOI: ( /j.ejca ) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
Fig. 6 European Journal of Cancer , 62-75DOI: ( /j.ejca ) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
Fig. 6 European Journal of Cancer , 62-75DOI: ( /j.ejca ) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions